|
| OSI-027 Basic information |
Product Name: | OSI-027 | Synonyms: | OSI-027;trans-4-[4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexanecarboxylic acid;4-(4-aMino-5-(7-Methoxy-1H-indol-2-yl)-1,2-dihydroiMidazo[5,1-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid hydrochloride;4-(4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f] [1,2,4]Triazin-7-yl)cyclohexanecarboxylic Acid;(1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[1,5-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid;ASP4786;OSI-027 trans-4-[4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexanecarboxylic acid;trans-4-[4-Amino-5-(7-methoxy-1H-indol-2-yl)imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexanecarboxylic acid OSI-027 | CAS: | 936890-98-1 | MF: | C21H22N6O3 | MW: | 406.44 | EINECS: | | Product Categories: | Akt;mTOR;Inhibitors;PI3K | Mol File: | 936890-98-1.mol | |
| OSI-027 Chemical Properties |
Melting point | >149°C (subl.) | density | 1.59 | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | solubility | DMSO (Slightly) | form | Solid | pka | 4.44±0.10(Predicted) | color | Pale Beige to Light Beige |
| OSI-027 Usage And Synthesis |
Description | The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that is central to two protein complexes, mTORC1 and mTORC2. These complexes are differentially regulated (e.g., only mTORC1 is sensitive to rapamycin ) and regulate different pathways. OSI-027 is an inhibitor of the catalytic site of mTOR and, as a result, inhibits both mTORC1 and mTORC2 (IC50s = 22 and 65 nM, respectively). It is selective for mTOR over phosphatidylinositol 3-kinase isoforms and DNA protein kinase. OSI-027 prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells at 10 μM. OSI-027 is effective in vivo, blocking the phosphorylation of targets of mTORC1 and mTORC2 and suppressing tumor growth in several different human xenograft models. | Uses | OSI-027 is a kinase inhibitor with anti-tumor activity, used in treatment of breast cancer.
| Definition | ChEBI: 4-[4-amino-5-(7-methoxy-2-indolylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-cyclohexanecarboxylic acid is a member of indoles. | target | mTORC | references | [1] bhagwat s v, gokhale p c, crew a p, et al. preclinical characterization of osi-027, a potent and selective inhibitor of mtorc1 and mtorc2: distinct from rapamycin. molecular cancer therapeutics, 2011, 10(8): 1394-1406. |
| OSI-027 Preparation Products And Raw materials |
|